Vilaprisan
Vilaprisan
Vilaprisan (pronounced: vi-la-pris-an) is a Selective Progesterone Receptor Modulator (SPRM) that is currently under investigation for its potential use in the treatment of uterine fibroids and endometriosis.
Etymology
The term "Vilaprisan" is a coined name, with no specific etymology. It is a trademarked name for a specific SPRM developed by Bayer AG.
Usage
Vilaprisan is being studied for its potential to treat conditions such as uterine fibroids and endometriosis by modulating the progesterone receptor. This receptor plays a crucial role in the growth and development of these conditions. By selectively modulating this receptor, Vilaprisan may be able to reduce the size of uterine fibroids and alleviate the symptoms of endometriosis.
Related Terms
- Selective Progesterone Receptor Modulator (SPRM): A type of drug that can either block or activate the progesterone receptor, depending on the context. SPRMs are being investigated for their potential use in a variety of gynecological conditions.
- Uterine fibroids: Noncancerous growths of the uterus that often appear during childbearing years.
- Endometriosis: A disorder in which tissue similar to the tissue that normally lines the inside of your uterus — the endometrium — grows outside your uterus.
- Progesterone receptor: A protein found inside cells that binds to the hormone progesterone and mediates its effects.
External links
- Medical encyclopedia article on Vilaprisan
- Wikipedia's article - Vilaprisan
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski